Silicon Valley billionaires are obsessed with 'reprogramming' their bodies for longevity. The first human trial suggests they may be onto something.

Key Points:

• Tech billionaires like Jeff Bezos, Peter Thiel, Yuri Milner, and Sam Altman are investing heavily in cellular reprogramming, a longevity strategy aimed at reversing age-related decline by rejuvenating cells.
• Life Biosciences has initiated the first human trial of cellular reprogramming to treat glaucoma, with early safety data showing no major side effects and preliminary signs of vision improvement in two out of three patients.
• Experts caution that while the results are promising, more data is needed to confirm the therapy’s effectiveness in truly reversing vision loss rather than just improving existing function.
• Encouraged by initial findings, the trial will increase dosage for upcoming patients, and if successful, the approach could be expanded to treat other age-related diseases such as arthritis, high blood pressure, and Alzheimer's.
• Several other Silicon Valley biotech firms, including Bezos-backed Altos Labs, Peter Thiel-backed New Limit, and Sam Altman-backed Retro Biosciences, are preparing for or planning human trials of cellular reprogramming therapies in the near future.